| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5424078 (Pediatric) | ABBVIE | Aqueous ophthalmic formulations and methods for preserving same |
Dec, 2012
(11 years ago) | |
| US9295641 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
| US9687443 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
| US10307368 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
| US6562873 | ABBVIE | Compositions containing therapeutically active components having enhanced solubility |
Jul, 2021
(2 years ago) | |
| US6627210 | ABBVIE | Compositions containing α-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
| US6673337 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
| US6641834 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
|
US6562873 (Pediatric) | ABBVIE | Compositions containing therapeutically active components having enhanced solubility |
Jan, 2022
(2 years ago) | |
|
US9295641 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
|
US9687443 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
|
US6627210 (Pediatric) | ABBVIE | Compositions containing α-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
|
US6673337 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
|
US6641834 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
| US8858961 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Sep, 2023
(7 months ago) | |
|
US8858961 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Mar, 2024
(a month ago) | |
Alphagan P is owned by Abbvie.
Alphagan P contains Brimonidine Tartrate.
Alphagan P has a total of 16 drug patents out of which 16 drug patents have expired.
Expired drug patents of Alphagan P are:
- US5424078*PED
- US9295641
- US9687443
- US10307368
- US6562873
- US6627210
- US6673337
- US6641834
- US6562873*PED
- US9295641*PED
- US9687443*PED
- US6627210*PED
- US6673337*PED
- US6641834*PED
- US8858961
- US8858961*PED
Alphagan P was authorised for market use on 16 March, 2001.
Alphagan P is available in solution/drops;ophthalmic dosage forms.
Alphagan P can be used as reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
The generics of Alphagan P are possible to be released after 02 March, 2024.
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 16 March, 2001
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
ALPHAGAN P family patents
